West Pharmaceutical Q2 Adjusted EPS Up 29%, Raises Guidance, GLP-1 18% of Sales, CEO Change Aug 31

West Pharmaceutical Services provides specialized packaging for nearly all injectable drugs, with high-margin products covering GLP-1 weight-loss drugs such as Ozempic and Zepbound, as well as complex biologics. After an inventory slowdown in 2024, the company's business has rebounded strongly. Adjusted earnings per share for the second quarter of 2026 rose 29% year over year, and the company raised its guidance for the second time this year. The company's balance sheet remains solid, and new Chief Executive Officer Michel Lagarde will take office at the end of August, having previously served as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific.

West Pharmaceutical Services operates in two segments: proprietary products and contract manufacturing. The proprietary products segment offers elastomer stoppers, pre-filled syringe systems, and wearable patch injectors, characterized by high-margin growth. The contract manufacturing segment manages high-precision assembly of drug delivery systems for medical device and pharmaceutical companies. The company operates globally, with facilities located near major pharmaceutical hubs, which helps mitigate the risk of localized supply disruptions.

Pharmaceutical containers are considered by global regulators to be part of the drug system itself. Replacing the packaging supplier for an approved drug requires validation testing lasting two to three years and costing millions of dollars. Therefore, once a pharmaceutical company selects West's packaging system and completes clinical trials, the drug typically maintains a single-supplier relationship throughout its commercial life. West's proprietary coatings, such as FluroTec, form a protective barrier between the drug and the container. Replicating these coatings and building sterile manufacturing plants requires billions of dollars in investment, creating a barrier to entry.

In 2025, a quarter of all U. S. drug approvals were biologics, and West said it supplies more than 90% of new molecules. In the second quarter, 43% of the company's revenue came from biologics. Market research firm IQVIA forecasts that the injectable drug market will grow from about US$700 billion in 2024 to US$1.2 trillion by 2030. GLP-1 therapies accounted for 18% of West's net sales in the second quarter. CEO Eric Green said on the July earnings call that global adoption of GLP-1 therapies is still in its early stages, and market access continues to expand.

Management at major pharmaceutical companies view oral weight-loss drugs as a way to expand the market, while injectables will remain the standard for high-dose, long-term weight management.

The share of West's high-value products in proprietary product segment net sales rose from about 60% in 2019 to about 75% in 2025. The Annex 1 sterile manufacturing standard, which took effect in Europe in 2023, requires pharmaceutical manufacturers to strengthen contamination control, driving adoption of high-value products such as NovaPure and FluroTec. Green said the company currently has nearly 800 projects in hand, up about 50% year over year, and this opportunity is expanding from Europe to the United States and other regions.

Lagarde will succeed Green as CEO on August 31, having previously managed most of Thermo Fisher's global business units. West has traditionally funded capacity expansion through stable cash flow and high capital returns, including building a large facility in Dublin, and has consistently returned capital to shareholders through dividends and share buybacks.